Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The most common ineffective production of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can be inherited or acquired. In 2014, According to a research article published in Professional Med J, 2014, entitled Frequency of Thrombocytopenia, the frequency of thrombocytopenia is higher for people aged 60 years and above, suffering from non-cirrhotic liver disease. However, rampant discovery coupled with the ability to clone thrombopoietin has resulted in new treatment opportunities for clinical manifestation.
Global Thrombocytopenia Treatment Market Taxonomy:
By Drug Class:
By Distribution Channel:
Approval of effective and safe drugs for thrombocytopenia treatment to provide momentum to the thrombocytopenia treatment market
More specific treatment plans usually depend on the underlying etiology of thrombocytopenia. In most cases the underlying cause of thrombocytopenia is not known, especially in the case of severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist developed by Shionogi Inc., received approval by Pharmaceuticals and Medical Devices Agency of Japan. Lusutrombopag helped enhance chronic liver disease (CLD) associated with thrombocytopenia for patients scheduled to undergo invasive procedures. Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and stimulates signaling pathways that trigger the proliferation and differentiation of bone marrow cells into megakaryocytes. Thus, increasing the blood platelet count. However, patients treated with Lusustrombopag further showed higher counts of blood leukocytes and erythrocyte. Furthermore, in June 2017, FDA accepted application for new oral investigational drug, Tavalisse (fostamatinib disodium), by Rigel Pharmaceuticals, Inc. This drug is designed to inhibit the spleen tyrosine kinase and treat patients suffering from chronic or persistent immune thrombocytopenia.
Another drug Eltrombopag by Novartis, an oral, non-peptide thrombopoietin receptor agonist has shown efficacy and safety for patients suffering from chronic immune thrombocytopenia (CIT). The use of this drug is approved in the U.S and registered in Europe. The low dose of Eltrombopag is effective and safe for the prevention of CIT. Case Reports Hematology, 2017, reports that long-term usage of thrombopoetin (TPO) receptor agonists is safe for patients suffering from chronic lymphocytic leukemia associated with Immune thrombocytopenia, as they are a non-immunosuppressive drugs.
Global Thrombocytopenia Treatment Market Dynamics
The thrombocytopenia treatment market is driven by increasing prevalence of thrombocytopenia globally. The risk of developing thrombocytopenia is much higher for chronic Hepatitis C cases. In 2014, according to World Health Organization (WHO), the prevalence of Hepatitis C was lower in Americas and Europe as compared to Africa and Pakistan, where the prevalence of chronic liver disorder was 4-6 % higher than that in Americas and Europe. Liver disease has become a socio economic and global health problem, as 60-80% of the population develops the disease. Furthermore, increasing government support for fast-track approval to discover newer treatments for this disorder and increasing investment in the development of new drugs by biotechnology and pharmaceutical companies are expected to propel growth of the thrombocytopenia treatment market during the forecast period. However, from 2023, thrombocytopenia treatment market is projected to witness a slowdown in growth due to patent expiration and increasing availability of generics of Promacta and MabThera.
Global Thrombocytopenia Treatment Market – Competitors
Major players in thrombocytopenia treatment market include 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.